Skip to main content
Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
- Frankel, Arthur E;
- Reddy, Renuka;
- DeSuza, Kayla R;
- Deeb, Khaled;
- Carlin, Aaron F;
- Smith, Davey;
- Xie, Yushuang;
- Naik, Eknath;
- Silver, Richard T;
- Hasselbalch, Hans C
Published Web Location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077319/No data is associated with this publication.
Abstract
An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.